Premium
Health Economical Aspects of Alzheimer Disease and its Treatment
Author(s) -
Wimo Anders,
Winblad Bengt
Publication year - 2001
Publication title -
psychogeriatrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.647
H-Index - 32
eISSN - 1479-8301
pISSN - 1346-3500
DOI - 10.1111/j.1479-8301.2001.tb00047.x
Subject(s) - pharmacoeconomics , disease , quality of life (healthcare) , alzheimer's disease , medicine , health care , business , gerontology , intensive care medicine , economic growth , economics , nursing , pathology
The health economics of Alzheimer disease (AD) is in a premature state, and there is a great need for methodological improvement. The scientific database is small although rapidly expanding. There is also a great interest in the pharmacoeconomics of AD amongst the drug authorities in different countries and in the pharmaceutical companies who are engaged in AD research, illustrating that it is a hot topic. In particular, aspects of quality of life among patients and caregivers, long term treatment effects and informal care should be the focus for methodological development.